


Volume 13, 23 October 2013

Publisher: Igitur publishing

URL: <http://www.ijic.org>

Cite this as: Int J Integr Care 2013; Annual Conf Suppl; [URN:NBN:NL:UI:10-1-114676](https://nbn-resolving.org/urn:nbn:nl:ui:10-1-114676)

Copyright: 

Poster Abstract

Availability and quality of data on pharmaceutical benefit financing components of health care system in United States, United Kingdom, Denmark, Germany, Italy and Poland

Tomasz Hermanowski, PhD, Professor, Head of Department of Pharmacoeconomics; InterQuality Project Leader, Medical University of Warsaw, Poland

Sylwia I. Szafraniec-Burylo, MD, PhD, Department -Centre for Monitoring and Analyses of Population Health Status and Health Care System, National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland

Urszula Cegłowska, MSc, Medical University of Warsaw, Poland

Aleksandra Drozdowska, MSc, Medical University of Warsaw, Poland

Dominika Duleba, MSc, Medical University of Warsaw, Poland

Marta Kowalczyk, MSc, Medical University of Warsaw, Poland

Aleksandra N. Krancberg, MSc, Medical University of Warsaw, Poland

Chris L. Pashos, PhD, United BioSource Corporation, Lexington, MA, USA

Andrzej Szczypior, MSc, Sopharm, Warsaw, Poland

Malgorzata Chmielewska, MSc, Medical University of Warsaw, Poland

Marcin Czech, MD, PhD, Associate Professor, Department of Pharmacoeconomics, Medical University of Warsaw, Poland

Correspondence to: **Tomasz Hermanowski**, Medical University of Warsaw, Poland,
E-mail: tomasz.hermanowski@wum.edu.pl

Abstract:

The abstract presents results of the “InterQuality Project – International Research Project on Financing Quality in Healthcare” funded by the 7th Framework Programme (FP7) for Research and Technological Development of the European Union.

Grant Agreement No: HEALTH-F3-2010-261369

Objective: To assess reliability, validity and completeness of data on pharmaceutical benefit financing components of health care in United States, United Kingdom, Denmark, Germany, Italy and Poland

Theory: Information and guidance used by authorities for decision making in the financing of pharmaceutical care should be reliable, valid and complete.

Methods: A systematic review of literature published in the last 10 years, found electronically in Medline, Embase, the Cochrane Library and SCOPUS, supplemented by a manual search, was conducted. Quality of publications was critically appraised using PRISMA [1], MOOSE [2] and STROBE [3] checklists. Contents of found literature were assessed in terms of consistency, coherence and strength.

Results: In total, 439 full text publications were included, of which 198 papers were assessed for quality. Of these, 24,6%, 31,2% and 22,1% publications presented high levels of: consistency, coherence and strength, respectively, and 4,3% presented concurrently high levels of all assessed areas. Several areas of weak data availability were identified. Discussion: No comparable analyses were found. Credible data were often unavailable. A questionnaire and a template helpful to collect data where more information is needed were developed, validated and will be sent to experts from InterQuality Consortium countries.

Conclusion: To improve the quality of information available to decision makers, so that it is more credible, multiple sources should be used.

Keywords

pharmaceutical benefit, United Kingdom, Denmark, germany, Italy, Poland

References:

1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *British Medical Journal*; 2009 Jul 21; 339:b2700
 2. Stroup DF, Berlin JA, Morton SC, Olkin I, et al. Meta-analysis of Observational Studies in Epidemiology, A Proposal for Reporting. *Meta-analysis Of Observational Studies in Epidemiology (MOOSE)*. *The Journal of the American Medical Association*. 2000 Apr 19; 283:15:2008-12
 3. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE), Explanation and Elaboration. *Epidemiology*. 2007 Nov; 18:6. p. 805-35
-